Man­u­fac­tur­ing roundup: Catal­ent to pro­duce low-cost ver­sion of nalox­one; CSL opens R&D site

Catal­ent will be man­u­fac­tur­ing a low-cost ver­sion of the opi­oid over­dose treat­ment nalox­one as part of a con­tract with Harm Re­duc­tion Ther­a­peu­tics.

Catal­ent plans to man­u­fac­ture the treat­ment at its fa­cil­i­ty in Mor­risville, NC. No fi­nan­cial de­tails on the deal were dis­closed.

Harm Re­duc­tion was grant­ed pri­or­i­ty re­view sta­tus for the NDA on its spray last year. The com­pa­ny has been work­ing on a nalox­one prod­uct since 2017. It is an­tic­i­pat­ing ap­proval in Ju­ly of this year and a US launch in ear­ly 2024.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN